-1750786316165.webp&w=3840&q=75)
2025 MLS Nashville | Bladder Cancer Updates in 2025
Overview
Dr. Garmezy highlighted the phase III NIAGARA trial, where durvalumab added to gemcitabine/cisplatin cut metastasis risk by 40 % (HR 0.6) and improved 24‑month MFS by 10%, extending eligibility to patients with creatinine clearance down to 40 mL/min and benefiting both prior CR and non‑CR groups. He also underscored ctDNA‑guided decision‑making and the promise of new targets such as FGFR inhibitors and Trop‑2 antibody–drug conjugates.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Benjamin Garmezy, MD
Date of Release
June 24th, 2025
